Test drug ZG0895.HCl in advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 trial studies ZG0895.HCl, a new experimental treatment, in people with advanced solid cancers. It’s mainly to check safety and how the body responds, and it may help by shrinking or controlling tumors if the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to understand the study and sign the informed consent form.
- You must be 18 to 75 years old, with an overall health score (ECOG) of 0 or 1.
- You must have advanced solid tumors that have no standard treatment option left or you could not tolerate standard treatment.
- You need at least one measurable tumor spot that doctors can track on scans.
- You must be healthy enough for treatment: life expectancy of at least 3 months, and prior side effects from earlier treatment should be back to near-normal (no more than mild problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
This trial is testing a new combination of two drugs (ZGGS18 and ZG005) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests an investigational tablet for people with advanced breast, ovarian, fallopian tube, primary peritoneal, or prostate cancer. It aims to see if the drug is safe and effective.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.